Profil
Dr. Cillian King is a Partner at EQT Life Sciences Group BV and a Founder at Koala Life Sciences BV.
He is on the Board of Directors at Sairopa B V, Muna Therapeutics ApS and QurAlis Corp.
Dr. King was previously employed as a Chairman-Supervisory Board by Allero Therapeutics BV and an Investment Manager by Swanbridge Capital Management BV.
He received his doctorate degree from Vrije Universiteit Amsterdam.
Postes actifs de Cillian King
| Sociétés | Poste | Début |
|---|---|---|
Muna Therapeutics ApS
Muna Therapeutics ApS BiotechnologyHealth Technology Engages in discovering and developing of therapies that slow and stop devastating neurodegenerative, alzheimer’s & parkinson’s diseases | Directeur/Membre du Conseil | - |
LSP Management Group BV
LSP Management Group BV Investment ManagersFinance EQT Life Sciences invests in companies located across the globe. The firm targets companies operating in the fields of therapeutics, medical devices, diagnostics and healthtech sectors. It provides financing for early and later stage capital requirements with an investment size of EUR 10 – 60 million. | Private Equity Investor | 01/01/2021 |
Koala Life Sciences BV | Fondateur | 01/01/2017 |
QurAlis Corp.
QurAlis Corp. Pharmaceuticals: MajorHealth Technology Develops precision medications | Directeur/Membre du Conseil | - |
Sairopa B V
Sairopa B V MiscellaneousMiscellaneous Develops medicines and functions as an investment holding company | Directeur/Membre du Conseil | 01/01/2021 |
Anciens postes connus de Cillian King
| Sociétés | Poste | Fin |
|---|---|---|
Swanbridge Capital Management BV
Swanbridge Capital Management BV Investment ManagersFinance Swanbridge Capital invests in Life Sciences companies located in the Rotterdam Science Tower we are in the very heart of the Life Sciences startup eco-system. The firm invests in early stage companies. | Private Equity Investor | 01/01/2021 |
Allero Therapeutics BV
Allero Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Develops immunotherapy treatment for allergic and autoimmune diseases | Président | 01/01/2021 |
Formation de Cillian King
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
LSP Management Group BV
LSP Management Group BV Investment ManagersFinance EQT Life Sciences invests in companies located across the globe. The firm targets companies operating in the fields of therapeutics, medical devices, diagnostics and healthtech sectors. It provides financing for early and later stage capital requirements with an investment size of EUR 10 – 60 million. | Finance |
Vrije Universiteit Amsterdam
Vrije Universiteit Amsterdam Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Swanbridge Capital Management BV
Swanbridge Capital Management BV Investment ManagersFinance Swanbridge Capital invests in Life Sciences companies located in the Rotterdam Science Tower we are in the very heart of the Life Sciences startup eco-system. The firm invests in early stage companies. | Finance |
QurAlis Corp.
QurAlis Corp. Pharmaceuticals: MajorHealth Technology Develops precision medications | Health Technology |
Allero Therapeutics BV
Allero Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Develops immunotherapy treatment for allergic and autoimmune diseases | Commercial Services |
Muna Therapeutics ApS
Muna Therapeutics ApS BiotechnologyHealth Technology Engages in discovering and developing of therapies that slow and stop devastating neurodegenerative, alzheimer’s & parkinson’s diseases | Health Technology |
Koala Life Sciences BV | |
Sairopa B V
Sairopa B V MiscellaneousMiscellaneous Develops medicines and functions as an investment holding company | Miscellaneous |
















